Lv3
268 积分 2023-12-06 加入
Disease Modulation Versus Modification: A Call for Revised Outcome Metrics in the Treatment of Thyroid Eye Disease
6天前
已完结
Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial
11天前
已完结
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial
11天前
已完结
Continuous Glucose Monitoring Metrics and Continuous Glucose Monitoring–Based Hypoglycemia, Including Duration, in Individuals with Type 1 Diabetes Switching to Once-Weekly Insulin Icodec: A Post Hoc Evaluation of ONWARDS 6
11天前
已完结
Early Real‐World Implementation of Once‐Weekly Insulin Icodec in Type 2 Diabetes
11天前
已完结
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
13天前
已完结
Cinacalcet Hydrochloride Reduces the Serum Calcium Concentration in Inoperable Parathyroid Carcinoma
18天前
已完结
The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies
18天前
已完结
Expanding the Potential Treatment of Thyroid Eye Disease
1个月前
已完结
Corticosteroids Versus Teprotumumab for the Treatment of Thyroid Eye Disease. Does Either Mitigate the Need for Additional Treatments?
1个月前
已关闭
皖公网安备34019202002308
